ASH 2024 | Comparing the outcomes of AYA and older adults with Ph- ALL in the PETHEMA LAL19 trial
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, comments on the unexpected similarity in outcomes between adolescent and young adult (AYA) and older adult patients with newly diagnosed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) treated in the PETHEMA LAL19 trial (NCT04179929). The outcomes of AYA patients were as expected, but the promising outcomes of patients aged 40 to 60 were surprising, mirroring that of AYA patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
It was a relatively surprising result for us because we expected that AYA patients, that is patients from 18 to 40 years, could have a superior outcome than patients older than 40 years, 40 to 60, 65 years, that were the oldest adults included in the trial. The outcome of the AYA patients was exactly what was expected and similar to that of other groups. But what surprised us is the good outcome of patients aged 40 to 60 years...
It was a relatively surprising result for us because we expected that AYA patients, that is patients from 18 to 40 years, could have a superior outcome than patients older than 40 years, 40 to 60, 65 years, that were the oldest adults included in the trial. The outcome of the AYA patients was exactly what was expected and similar to that of other groups. But what surprised us is the good outcome of patients aged 40 to 60 years. It’s absolutely the same as the AYA patients. That for us and I think that for the scientific community, it’s a good deal.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
